Back to top
more

Argenx (ARGX)

(Real Time Quote from BATS)

$377.23 USD

377.23
237,335

+15.02 (4.15%)

Updated Apr 23, 2024 02:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

GSK Gears Up for Q1 Earnings: Here's What to Expect

by Zacks Equity Research

We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.

Viking (VKTX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Devoid of marketed drugs, investors will focus on Viking Therapeutics' (VKTX) pipeline updates when it reports first-quarter earnings results.

Why Argenx's (ARGX) Stock Price Moved Up 11% on Thursday

by Zacks Equity Research

Argenx (ARGX) surges after a Japanese rival posted disappointing results from a late-stage study on its investigational drug for generalized myasthenia gravis.

Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last?

by Zacks Equity Research

Argenx (ARGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Is a Surprise Coming for argenx (ARGX) This Earnings Season?

by Zacks Equity Research

argenx (ARGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Can Rising Operating Costs Affect Acadia's (ACHC) Q4 Earnings?

by Zacks Equity Research

Acadia Healthcare's (ACHC) fourth-quarter results are likely to reflect increasing patient days and admissions.

Can Higher Admissions Drive Universal Health (UHS) Q4 Earnings?

by Zacks Equity Research

Universal Health's (UHS) fourth-quarter results are likely to reflect improved performances from the Acute Care Hospital Services and Behavioral Health Care Services businesses.

How Argenx (ARGX) Stock Stands Out in a Strong Industry

by Zacks Equity Research

Argenx (ARGX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Biotech Stock Roundup: CGEN Up on GILD Deal, MRNA Gains on Study Data & More

by Zacks Equity Research

Compugen (CGEN) and Moderna (MRNA) are in the news on collaboration and study updates, respectively.

argenx (ARGX) Tanks on Top-Line Data From Pemphigus Study

by Zacks Equity Research

argenx's (ARGX) phase III ADDRESS study, evaluating efgartigimod subcutaneous for treating pemphigus, fails to meet primary and secondary endpoints. Stock falls.

Halozyme (HALO) Q2 Earnings & Revenues Beat, 2023 View Raised

by Zacks Equity Research

Halozyme (HALO) shares rise 4% in the after-market trading hours on better-than-expected second-quarter 2023 results, boosted by collaboration and royalty revenues. Management raises its 2023 guidance.

Biotech Stock Roundup: BBIO, ARGX Soar on Study Results, APLS Down on Safety Issues

by Zacks Equity Research

Regulatory and key pipeline updates from BridgeBio (BBIO) and argenx (ARGX) are in focus in the biotech sector.

Halozyme Therapeutics (HALO) Soars 5.4%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Halozyme Therapeutics (HALO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

argenex SE (ARGX) Surges 27.8%: Is This an Indication of Further Gains?

by Zacks Equity Research

argenex SE (ARGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

All You Need to Know About argenex SE (ARGX) Rating Upgrade to Buy

by Zacks Equity Research

argenex SE (ARGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Perrigo (PRGO) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.

Editas (EDIT) Soars 20.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Editas (EDIT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Geron (GERN) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Devoid of marketed drugs, investors will focus on updates on Geron's (GERN) lead pipeline candidate when it reports its fourth-quarter earnings.

Perrigo (PRGO) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.

Immunocore Holdings PLC Sponsored ADR (IMCR) Soars 6.9%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Immunocore Holdings PLC Sponsored ADR (IMCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Halozyme (HALO) Down 9.2% on Weak 2023 Financial Guidance

by Zacks Equity Research

Though Halozyme (HALO) expects a year-over-year increase in revenues and earnings for 2023, the company's guidance fell short of Wall Street expectations.

argenex SE (ARGX) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

argenex SE (ARGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Halozyme (HALO) Stock Rises 35% in the Year so Far: Here's Why

by Zacks Equity Research

Halozyme (HALO) is gaining on its proprietary drug delivery technology, ENHANZE. It expects strong revenues on the back of robust demand for its new partnered drugs.

Why Earnings Season Could Be Great for argenx (ARGX)

by Zacks Equity Research

argenx (ARGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Sundeep Ganoria headshot

4 Biotech Stocks Set to Outpace Q3 Earnings Estimates

by Sundeep Ganoria

Let us take a look at some biotech stocks, ARGX, BMRN, LLY and GMAB, which are poised to beat on third-quarter earnings.